Indian Journal of Dental ResearchIndian Journal of Dental ResearchIndian Journal of Dental Research
HOME | ABOUT US | EDITORIAL BOARD | AHEAD OF PRINT | CURRENT ISSUE | ARCHIVES | INSTRUCTIONS | SUBSCRIBE | ADVERTISE | CONTACT
Indian Journal of Dental Research   Login   |  Users online:

Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size         

 


 
ORIGINAL RESEARCH Table of Contents   
Year : 2021  |  Volume : 32  |  Issue : 2  |  Page : 192-198
Hydroxychloroquine- A new treatment option for erosive oral lichen planus


1 Department of Periodontics, S.C.B Dental College and Hospital, Cuttack, Odisha, India
2 Department of Prosthodontics and Crown and Bridge, S.C.B Dental College and Hospital, Cuttack, Odisha, India
3 Department of Pedodontics and Preventive Dentistry, S.C.B Dental College and Hospital, Cuttack, Odisha, India

Correspondence Address:
Dr. Subash Chandra Raj
Department of Periodontics, S.C.B Dental College and Hospital, Cuttack - 753007, Odisha
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijdr.IJDR_943_20

Rights and Permissions

Context: Oral Lichen planus (OLP) is a chronic, debilitating, immune-mediated disease whose management is considered a challenge in medical science. Aims: To quantitatively evaluate the effect of administration of enteral hydroxychloroquine (HCQS) as a monotherapy for six months on the extent and severity of erosive OLP using reticular score, erythema score and ulcerative score (REU score), and to subjectively evaluate the success of HCQS as a therapeutic drug for OLP-e using Tel Aviv-San Francisco Scale, visual analogue scale (VAS) and severity of burning sensation (BURN score). Settings and Design: Prospective clinical trial. Methods and Material: A total of 45 subjects received 200 mg of HCQS bid for six months. REU, VAS, BURN scores and Tel Aviv-San Francisco Scale readings were taken at the beginning of the study (baseline) and three- and six-month intervals post administration of enteral HCQS. Subjects were examined for any adverse drug outcomes for one year after the cessation of enteric HCQS therapy. Data were analysed with SPSS version 25. Results: There was a stark reduction in REU, VAS and BURN scores during the study period, with a statistically significant reduction (P < 0.05) seen at three- and six-month time intervals as compared to baseline. Further, the mean of change in R, E and U scores showed a statistically significant difference, with the highest reduction seen at baseline to six-month time interval. The Tel Aviv-San Francisco Scale showed 70%–100% remission in disease in more than 70% of subjects. Conclusions: Enteral HCQS can be considered a viable treatment option for the enigma that is erosive OLP.


[FULL TEXT] [PDF]*
Print this article     Email this article

 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
  Citation Manager
 Access Statistics
  Reader Comments
  Email Alert *
  Add to My List *
 
 

 Article Access Statistics
    Viewed586    
    Printed12    
    Emailed0    
    PDF Downloaded26    
    Comments [Add]    

Recommend this journal